Berenberg has initiated coverage of BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), citing their leadership positions in mRNA medicine. The investment firm started BioNTech (BNTX) with a buy rating ...
Other drug manufacturers declined in the days following the nomination. Pfizer and Moderna have declined 6.9% and 6.2% ...
Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of ...
Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...
BioNTech (NASDAQ:BNTX) stock rose 1.9% after Evercore ISI upgraded its stance on the drugmaker to ‘outperform’ from ‘in line’ ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
TipRanks on MSN8h
Moderna initiated with a Hold at BerenbergBerenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says ...
Evercore ISI upgraded BioNTech (BNTX) to Outperform from In Line with a price target of $125, up from $110. The firm says it has been “growing increasingly constructive for some time now.” The upgrade ...
LONDON — Robert F. Kennedy Jr. has been a vocal critic of the pharma industry. He’s said it’s corrupted U.S. health agencies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback